29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype by Monin, Marie-Lorraine et al.
29 French adult patients with PMM2-congenital disorder
of glycosylation: outcome of the classical pediatric
phenotype and depiction of a late-onset phenotype
Marie-Lorraine Monin, Cyril Mignot, Pascale De Lonlay, Be´ne´dicte He´ron,
Alice Masurel, Miche`le Mathieu-Dramard, Catherine Lenaerts, Christel
Thauvin, Marion Ge´rard, Emmanuel Roze, et al.
To cite this version:
Marie-Lorraine Monin, Cyril Mignot, Pascale De Lonlay, Be´ne´dicte He´ron, Alice Masurel, et
al.. 29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the
classical pediatric phenotype and depiction of a late-onset phenotype. Orphanet Journal of




Submitted on 3 Feb 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Monin et al. Orphanet Journal of Rare Diseases 2014, 9:207
http://www.ojrd.com/content/9/1/207RESEARCH Open Access29 French adult patients with PMM2-congenital
disorder of glycosylation: outcome of the classical
pediatric phenotype and depiction of a late-onset
phenotype
Marie-Lorraine Monin1,2, Cyril Mignot1,3, Pascale De Lonlay4, Bénédicte Héron5, Alice Masurel6,
Michèle Mathieu-Dramard7, Catherine Lenaerts8, Christel Thauvin6, Marion Gérard9, Emmanuel Roze10,
Aurélia Jacquette1,3, Perrine Charles1, Claire de Baracé11, Valérie Drouin-Garraud12, Philippe Khau Van Kien13,
Valérie Cormier-Daire14, Michèle Mayer5, Hélène Ogier15, Alexis Brice1,2, Nathalie Seta16 and Delphine Héron1,3*Abstract
PMM2-CDG (formerly known as CDG Ia) a deficiency in phosphomannomutase, is the most frequent congenital
disorder of glycosylation. The phenotype encompasses a wide range of neurological and non-neurological
manifestations comprising cerebellar atrophy and intellectual deficiency. The phenotype of the disorder is well
characterized in children but the long term course of the disease is unknown and the phenotype of late onset
forms has not been comprehensively described. We thus retrospectively collected the clinical, biological and
radiological data of 29 French PMM2-CDG patients aged 15 years or more with a proven molecular diagnosis
(16 females and 13 males). In addition, thirteen of these patients were reexamined at the time of the study to
obtain detailed information. 27 of the 29 patients had a typical PMM2-CDG phenotype, with infantile hypotonia,
strabismus, developmental delay followed by intellectual deficiency, epilepsy, retinitis pigmentosa and/or visceral
manifestations. The main health problems for these patients as teenagers and in adulthood were primary ovarian
insufficiency, growth retardation, coagulation anomalies and thrombotic events, skeletal deformities and osteopenia/
osteoporosis, retinitis pigmentosa, as well as peripheral neuropathy. Three patients had never walked and three lost
their ability to walk. The two remaining patients had a late-onset phenotype unreported to date. All patients (n = 29)
had stable cerebellar atrophy. Our findings are in line with those of previous adult PMM2-CDG cohorts and points to
the need for a multidisciplinary approach to the follow up of PMM2-CDG patients to prevent late complications.
Additionally, our findings add weight to the view that PMM2-CDG may be diagnosed in teenage/adult patients with
cerebellar atrophy, even in the absence of intellectual deficiency or non-neurological involvement.
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Congenital Disorders of Glycosylation (CDGs) are rare
metabolic diseases with various clinical manifestations
and a wide range of severity [1,2]. Phosphomannomutase
2 - Congenital Disorder of Glycosylation (PMM2-CDG,
formerly CDG Ia, ORPHA79318, MIM 212065) is by far
the most frequent type of CDG with more than 800
patients reported worldwide in 2009 [3] (about 1:20.000
to 1:50.000 births worldwide). First described in 1980
[4], PMM2-CDG is due to the failure of the phospho-
mannomutase [5] (PMM2 gene [6]) which catalyses the
transformation of mannose-6-Phosphate into mannose-
1-Phosphate, substrate for the dolichol-pyrophosphate-
oligosaccharides, secondarily branched on proteins in
the endoplasmic reticulum. The diagnosis of PMM2-
CDG is provided by a screening showing evidence of the
abnormal glycosylation of serum N-glycoproteins test
and confirmed by a PMM2 activity assay and PMM2
sequencing.
Most articles reporting series of PMM2-CDG patients
focused on the pediatric population because the diagno-
sis is usually established during childhood [7]. Though a
subset of infants are affected by a severe neurological-
multivisceral form with life-threatening events and a
20% reported mortality rate, many of them have promin-
ent neurological involvement that can be associated with
mild or no visceral disorders [8,9]. The progressive nature
of PMM2-CDG has been recognized since its earliest
descriptions [10], the long-term course of the disease
through adolescence and adulthood has been described
for 26 patients in six different articles [7,11-16]. Our
cohort of 29 adolescent and adult PMM2-CDG patients
provides additional data on the outcome of patients
with this disorder. It also confirms that PMM2-CDG
may be diagnosed in adolescence or in adulthood for
patients with a mild phenotype [12].
Methods
We retrospectively collected the clinical observations of
French PMM2-CDG patients aged 15 years or more with
biallelic PMM2 mutations. Clinical, biological, radiological
and electrophysiological data were obtained from the
medical files of all patients and 13 of them were re-
examined during the previous two years, in accordance to
the law and ethical requirements. Motor disability was
evaluated with the Spinocerebellar Degeneration Functional
Score (SDFS: 0: no functional handicap; 1: no functional
handicap but signs at examination; 2: mild, able to run; 3:
moderate, unable to run; 4: severe, walking with one stick,
unlimited walking; 5: walking with two sticks; 6: unable
to walk, requiring a wheelchair; 7: bedridden) [17,18].
All blood samples were collected after obtaining in-
formed consent. For all the patients at the time of diag-
nosis, whatever their age, screening of PMM2-CDG wasperformed in the Laboratory of Biochemistry of the
Hospital Bichat-Claude Bernard in Paris (N. Seta) and
evidenced abnormal glycosylation of serum glycoproteins
and reduced activity of leukocytes (N > 6.0 U/g protein)
and/or fibroblasts (N > 4.0 U/g proteins) phosphomanno-
mutase (PMM) [19]. The molecular study of PMM2 gene
was performed as previously reported [6].
Results
29 patients from 25 families aged from 15 to 49 years
were included (mean 27.4 years). One patient (#13) died
at 25 years of age. There were 16 males and 13 females
(sex ratio of 1.2) and three sib pairs. Most patients were
from France, 3 patients were from Spain, Portugal and
West Indies.
From the neonatal period to childhood (Table 1)
Normal pregnancies and deliveries were reported in 20/29
patients, in three cases where pregnancies included
hydramnios, eclampsia and/or prematurity. Six patients
had low birth weight, three with normal pregnancy and
normal fetal growth parameters.
First signs of PMM2-CDG were identified during the
first months of life in 10/20 patients, and before the end
of the first year in all but one. Visceral signs (vomiting,
diarrhoea, liver failure) were present in 8/20 patients and
were always associated with truncal hypotonia and strabis-
mus during the first year. When visceral signs were absent
(n = 12/20), hypotonia, strabismus and psychomotor delay
were the main revealing signs and remained in adulthood.
Stroke-like episodes with full recovery occurred in two
patients. A single stroke-like episode occurred at 3 years
of age in one patient during a venous thrombosis. The
second patient presented with three episodes between 3
and 13 years of age. No episode was reported for any
patient after 15 years.
Patients #11 and #14 had no reported signs suggesting
PMM2-CDG during childhood, except patient #11 who
had an isolated esotropia starting at two months of age.
Teenage and adulthood (Table 2)
Neurological involvement
Cerebellar ataxia was the leading sign for diagnosis
and was present in all patients. Gait ataxia was present
during childhood in all walking patients and did not
appear to worsen with time. 15/27 patients acquired
independent walking (without aid), including two before
the age of 18 months, and 13 between 18 months and
14 years of age (mean age for all was 3.8 years, median
age 2.5). Eleven patients acquired walking with aid and
three patients never walked. In the former group, three
patients lost their ability to walk during adulthood
because of severe kyphoscoliosis causing respiratory
Table 1 Genotypes of the 29 PMM2-CDG patients, first signs at onset and age at the molecular diagnosis
Patient (current age, gender) Genotype First signs (age) Age at molecular diagnosis
1*(24, F) F157S/C241S Ataxia and strabismus (first year) 9
2*(26, M) F157S/C241S Psychomotor delay (6 m) 11
3* (15, F) F157S/C241S Psychomotor delay (first year) First year
4 (20, M) R141H/C241S Strabismus, hypotonia (at birth) 2,5
5 (31, M) R141H/C241S Gait ataxia (18 y) 24
6%(46, M) R141H/C9Y Hypotonia (at birth) 33
7%(49, M) R141H/C9Y Diarrhea, hypotonia (at birth) 36
8 (20, F) R141H/C9Y NA 4
9 (25 death, F) R141H/F119L NA 21
10 (24, M) R141H/F119L Infections, thrombocytopenia,
liver failure, syncopes (3 w)
13
11 (19, F) R141H/I153T NA 2
12 (22, F) R141H/I153T NA (8 m) 12
13 (27, M) R141H/P113L Digestive troubles (at birth) 14
14 (34, F) R141H/P113L Vomiting (at birth) 25
15 (19, F) R141H/G214S NA (7 m) 10
16 (44, F) R141H/Q177H Hypotonia (at birth) 40
17 (22, M) R141H/V129M Hypotonia, liver failure (at birth) 2 months
18 (21, M) R141H/E139K NA (first months) 7
19 (31, F) R141H/T226S NA 16
20 (17, F) R141H/C103F NA 14
21 (32, F) R141H/ I132T Psychomotor delay (first year) 16
22 (32, M) I132T/P20S + IVS1 + 1G > T Diarrhea, feeding difficulties (at birth),
generalized edema (3 w)
22
23 (28, M) R141H/A108V Psychomotor delay (6 m) 15
24 (25, F) A108V/R123Q Strabismus, hypotonia (at birth) 22
25$ (25, M) T18S/IVS3 + 2 T > C NA 13
26$ (25, M) T18S/IVS3 + 2 T > C NA 8
27 (24, F) G255A/E139K Feeding difficulties (3 m) 13
28 (39, F) T237R/R162W Strabismus (2 m) 27
29 (35, F) R162W/IVS3 + 1G > A Psychomotor delay (first year) 22
NA: not available; *$%: siblings; m: month; y: year; w: week.
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and exercise. During the course of the disease and
at last examination, slowness and dysmetria were
more often noticed than intentional tremor. Usual
rating scales of ataxia, such as the Scale for the
Assessment and Rating of Ataxia, could not be used
with the 13 patients reexamined for this study
because of their marked slowness and difficulties
with comprehension. At last examination, patients
who acquired independent walking were still walking
without aid (n = 15/29, SDFS <4), seven patients
needed aid (SDFS = 4 or 5), five patients were
wheelchair bound (SDFS =6) and two were
bedridden (SDFS =7).Brain MRI or TDM showed cerebellar atrophy in all
patients and was sometimes associated with mild pons
atrophy (Figure 1, upper panel). In three patients
with repeated brain imaging, the atrophy did not
appear to progress, even through adulthood.
Apart from cerebellar anomalies, symmetric,
confluent white matter hyperintensities were
found in 4/7 patients on brain MRI performed
after 15 years of age.
Epilepsy was diagnosed in 8/23 patients and always
started before age 15, mainly between 3 months and
3.5 years of life. Electroencephalographic recordings
(EEG) showed diffuse or focal slow background activity
in three patients and anterior fast rhythms (without
Table 2 Clinical description of the 29 PMM2-CDG adult
patients
Mean age at last examination in years (range) 24 (15–49)
Gender M/F 13/16
Short stature 13/25 (52%)
Ovarian failure 16/16 (100%)
Cerebellar ataxia 29/29 (100%)





Mean age at walking in years (range) 4 (1,25-14)
Neuropathy 13/22 (59%)
Skeletal involvement Kyphoscoliosis 17/24 (71%)
Osteopenia/osteoporosis 7/7 (100%)





Venous thrombosis 5/21 (24%)
Stroke-like episodes (adulthood) 0/18 (0%)
Reading/writing capacity Acquired 6/15 (40%)
Able to deciphering 4/15 (27%)
Unable to read/write 5/15 (33%)
Language abilities Speak sentences 18/27 (67%)
Speak words 6/27 (22%)
Absent language 3/27 (11%)







Professional status Sheltered work 9/22 (41%)
Unable to work 7/22 (32%)
School age (15–18 years) 6/22 (27%)
Living place Independent 1/16 (6%)
Institution 5/16 (31%)
*Certificate of competence, High School Diploma.
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well-controlled with antiepileptic therapy, mostly with
a single drug and with two drugs or more in two-thirds
of the cases. Only occasional seizures occurred in adult
patients.
22/24 patients had delayed development and
intellectual disability (ID) of variable severity. 10/15
patients with informative data achieved the ability to
read at least a few words and six patients could read
correctly and write by hand or with the use of a
keyboard. None of these patients had a typicaleducation: four patients followed an adapted program
in “normal” schools but the others were enrolled in
specialized schools for mentally and physically disabled
children. Among 17 patients of working age, one
worked as a farm-worker and another obtained an
internship in business. Three patients were still
working in specialized employment for people
with disabilities and four others were waiting for
such employment. The eight other patients were
dependent on their family at home or attending
occupational centers.
Signs of peripheral neuropathy were reported for
22 patients and found in 13 after the age 15, mainly
abolished osteotendinous reflexes, distal amyotrophy
and sensitive alteration. Nerve conduction velocity
(NCV) had been measured in nine patients. Two
patients had a normal exam, axonal neuropathy was
diagnosed in one and demyelinating neuropathy in the
six others (exam performed between 1 and 49 years of
age). NCV recordings were repeated in three cases, and
demonstrated a slow worsening of demyelination over a
period of 9 years in one patient and over a period of
3 years in adulthood for the other, with additional
involvement of the upper limbs.
Psychological aspects. Although PMM2-CDG
patients were often described as affable and
cheerful, eight patients in our cohort developed
psychiatric symptoms, including aggressive
behaviour (n = 5), apathy (n = 2) and depression
(n = 1). These difficulties could contribute to the loss of
autonomy, as exemplified by the depressed patient #22
who lost the ability to walk.
Vascular events and haematological features
Coagulation parameters were altered in 15/17 patients
(88%) including significant decrease of factors IX, XI and
XII, and less frequently of antithrombin III, protein C and
protein S. Five patients presented blood count abnormal-
ities, i.e. neutropenia (n = 2) or thrombocytopenia (n = 4).
Five patients had venous thrombotic events in lower or
upper limbs. The earliest venous thrombosis occurred in
patient #7 at 3 years of age while the four others occurred
in adolescent or adult patients at 17, 22, 41 and 44 years
of age. Two patients had a single event and three had
recurring events. Clotting factors IX and XI, as well as
antithrombin III, were decreased during these events in all
five patients, but the measures were not significantly lower
than those collected before or after these events during
routine biological assessments. Chronic low levels of
protein C and protein S and thrombocytopenia were
found in 2/5 with thrombotic events.
One patient was treated with long-term anticoagulant
therapy, another with antiplatelet therapy after a period
of anticoagulant therapy and the third had a temporary
Figure 1 Brain MRI and morphological aspects of adult PMM2-CDG. Upper panel. Brain MRI of patient #19 at 16 years old. T1-weighted
sagittal (A) and frontal (B) images showing severe atrophy of the cerebellum, including vermis and hemispheres, and less atrophied pons. Lower
panel. Picture of a 32 year-old patient with severe ataxia, neuropathy and severe intellectual disability (C). Picture of a 45 year-old patient showing
the abnormal fat repartition typical of PMM2-CDG (D).
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rence of thrombosis with antithrombotic therapy.
Ophthalmological involvement
25/28 patients had strabismus at some point during their
lifetime and which persisted to adulthood for 24 patients.
At least four patients underwent one or two strabismus
surgeries, with poor outcome. No worsening was observed
but one patient developed amblyopia. Severe associated
refraction problems were observed in three patients: two
with severe myopia (patients #4 and #8) and one with
severe hypermetropia.
Retinitis pigmentosa was diagnosed in 10/19 patients
in whom fundus oculi and/or an electroretinogram (ERG)was available. It was progressive in one patient with a nor-
mal ERG at age 45 and a diagnosis of retinitis pigmentosa
at age 49.
Skeletal involvement
Kyphoscoliosis was noticed in 17/24 patients and ap-
peared before adolescence in all cases. Kyphoscoliosis
worsened with time, causing severe thoracic deformities
during adolescence in three patients aged 30 years or
more. A fourth patient had an earlier thoracic deformation
with severe respiratory failure at age 15.
Bone densitometry was carried out in five patients
aged 15 to 25 years and showed osteopenia in all of
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as hip or tibial fracture in two patients.
Growth parameters and endocrine functions
Head circumference was reported to be normal in all 14/
29 patients where data was available. Thirteen patients
had growth retardation (height and weight from −2 to −4
standard deviations from the mean, SD). Growth parame-
ters of others were around or beyond the mean. Correl-
ation between height and weight remained harmonious,
without obesity or underweight. No patients had thyroid
dysfunction (n = 0/13); 2/6 patients with cortisol assess-
ment had a low cortisol rate at 8 am.
All female patients (n = 16) had primary ovarian insuffi-
ciency. At least six patients received hormone replacement
therapy (commencement between 12 to 15 years of age).
Hypocholesterolemia was found in 6/15 patients, hypoal-
buminemia in 3/7 and elevated liver enzymes in 2/16.
Morphological aspects
Inverted nipples and abnormal fat repartition, which are
typical morphological signs present in the first months
of life, were reported in 3/11 and in 7/19 adult patients
of the cohort respectively (Figure 1, lower panel), where
data was available. No obvious recognizable facial dys-
morphism was identified in adults.
Exceptionally mild phenotypes
As mentioned above, patient #11 had a squint since
the age of 2 months. She developed normally, walked
at 15 months, and obtained a high school diploma. At
17 years old, she had amenorrhea revealing primary ovar-
ian insufficiency. An acute psychotic episode occurred at
27 years of age during which she was hospitalized. Mild
gait ataxia was observed and brain MRI revealed a ver-
mian atrophy leading to the screening for CDG. She is
presently independent in daily life but is unable to run.
Patient #14 walked at 2 years, had normal language
acquisition and a normal education despite learning
difficulties. Brain MRI was performed at 18 years of
age because of mild gait ataxia and revealed vermian
atrophy. Positive CDG screening led to further investiga-
tions that assessed axonal neuropathy and decreased
clotting factors IX and XI. He presently has no limitations
in daily life.
Discussion
In our cohort, the diagnosis of PMM2-CDG was made at a
mean age of 17 years (range 1–40 years) while all but two
patients had signs before the end of the first year of life. In
other adult patients in the available literature, the diagnosis
was made at a mean age of 14 years [8,12,16] and “after the
age of 15 years in 10 of the patients” reported by Stibler
et al. [13]. The role of phosphomannomutase has beenknown since 1984 [5], and PMM2-CDG was identified as a
distinct phenotype in the late 1980’s-early 1990’s [20].
However, its molecular diagnosis has been available since
1997 [6] only, which explains the delay in molecular
diagnosis for the oldest patients of adult samples. Given its
frequency and the number of patients diagnosed world-
wide, in the present day PMM2-CDG would undoubtedly
be diagnosed earlier, i.e. in childhood. However, it may still
be underdiagnosed in adolescent/adult [21] patients with
the mildest phenotype as reported here.
Retrospective analysis of PMM2-CDG manifestations in
childhood
Pregnancy, delivery, and the first years of life of our
patient cohort were similar to those in the available lit-
erature [8,22]. First signs occurred before the end of the
first year of life in 27/29 patients, in accordance with the
age of onset reported in the literature [8]. Strabismus
and hypotonia were the most frequent initial signs, as has
been previously reported [8], and hepato-gastro-intestinal
(failure to thrive, diarrhoea, vomiting) were frequent. All
walking patients with pediatric onset acquired walking
with a delay, as reported by Stibler et al. [13], at a mean
age of 4 years. Fifty-two percent of the patients reported
here walked independently, which in line with a previous
report [8], and more than two others (23% in Sibler et al.
and 8% in Kjaergaard et al.) [13,14]. All 27 patients with
early signs had mild to severe ID and cerebellar atrophy.
Though the abnormal subcutaneous fat distribution
described in children has been said to disappear with time,
it was still present in 37% of our patients (Figure 1, lower
panel). Therefore, when present, it can be a clue to
indicate the diagnosis in adults with cerebellar ataxia.
Consequently, PMM2-CDG is a recognizable phenotype
in most patients, even for those who eluded diagnosis dur-
ing childhood.
The functional motor outcome of PMM2-CDG patients
tended to differ according to the extent of the invol-
vement of differing systems at onset: 7/8 patients with the
neurological-multivisceral form required aid for walking
or were unable to walk at last evaluation (SDFS ≥5),
whereas 9/12 patients with the neurological phenotype
walked independently (SDFS ≤3). This suggests that neo-
natal/infantile visceral PMM2-CDG is generally followed
by a more severe neurological outcome. However, visceral
manifestations do not always imply severe CNS involve-
ment, particularly when onset is later in life [12,16].
PMM2-CDG in adolescence and adulthood
It has been reported repeatedly that cerebellar ataxia is
not progressive in PMM2-CDG [13,23], which we obser-
ved in our cohort. However, motor disability may worsen
with time and may lead to the loss of independent
ambulation and autonomy. Peripheral neuropathy, which
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and in other reports [13,16], but not in all cohorts
[12], is a possible explanation for this loss of func-
tion. Progressive orthopedic involvement caused by
hypotonia, osteopenia and/or neuropathy has also been
shown to be a major issue in ageing PMM2-CDG patients
[15,23,24].
Though 35% of the patients of our cohort were epilep-
tic, no patient had a first seizure in adolescence/adult-
hood and epilepsy was well-controlled with one or more
anti-epileptic drugs in all patients, as has been shown in
other adult samples [12,15]. Stroke-like episodes have
not been reported after childhood in other adult cohorts
[13,23]. Our sample confirms that stroke-like episodes
do not seem to correspond to the adult phenotype of
PMM2-CDG.
Only one third of adult patients reported here had
short stature, which is less than in other cohorts (85% in
Stibler et al.) [13]. All female patients within our cohort
had delayed puberty with primary ovarian insufficiency,
as described in the literature [25].
Depression or behavioral issues reported in patients of
our cohort point to the deleterious effect of the lack of
stimulation in this vulnerable population of patients.
Five patients of our cohort had venous thrombotic
events, including three during adulthood. It is well-known
that the prevalence of thrombosis in PMM2-CDG patients,
evaluated at 14% for all ages [26,27], is partly related to an
imbalance between pro- and anti-thrombotic factors.
Though most events are unique, three patients reported
here had recurring events. Linssen et al. recommend yearly
assessment of anti-thrombin III, protein C and protein S,
as well as avoidance of elective surgery and immobility to
prevent thrombosis.
One third of the patients reported here had retinitis
pigmentosa, which is less than in other reports (100% in
Stibler et al., 60% in de Lonlay et al.) and in ophthal-
mological paediatric samples [28,29]. This is likely due
to the lack of ophthalmological follow-up in another
third of our patients. No patients complained of visual
loss in diurnal or nocturnal vision, but intellectual defi-
ciency may impair the ability to judge this loss for some.
Retinitis pigmentosa was diagnosed at the age of 49 years
for patient #22, who had regular ophthalmological exami-
nations. Progressive retinitis pigmentosa has been reported
in the literature [15], though it had onset in childhood and
seems to remain stable over time in other reports [12,13].
Our study suggests that routine ophthalmological
examinations continue to be useful in adult PMM2-
CDG patients.
Scoliosis and thoracic deformities were recorded in
70% of our patients and in 80-100% of other adult
patients in the literature [12,15]. Osteopenia or osteo-
porosis was present in all patients of our cohort,sometimes with severe clinical implications. This has been
mentioned in other samples of adult PMM2-CDG patients
[16,23] and implies the importance of specific moni-
toring to prevent fractures.
All of these data underline the need for attentive, multi-
disciplinary approach to adult PMM2-CDG patients with
teams that include neurologists, orthopedic surgeons and
experts in rehabilitation medicine [15].Teenage/adult patients with a late-onset phenotype
The diagnosis of PMM2-CDG in patients #11 and #14
of our sample shows that the absence of specific signs in
childhood, or abnormal or subnormal intellectual func-
tioning, does not rule out the presence of the condition.
A single pediatric patient with cerebellar hypoplasia and
borderline cognitive dysfunction has been reported [30].
Other PMM2-CDG patients reported so far with a mild
phenotype had cerebellar atrophy associated with mild
to moderate ID [16], even when diagnosed in adulthood
[12,15]. The two patients reported here had strikingly
late manifestations of onset suggesting that the onset of
symptoms of PMM2-CDG may occur in teenage or
adulthood in some individuals. Krasnewich et al., after
Schoffer et al. [30], stated that PMM2-CDG “should be
considered in adults with a history of multi-organ system
involvement” [15]. Moreover, we didn’t correlate genotype
to phenotype in this study, due to the variety of genotypes,
with only compound heterozygous mutations, even if
siblings with same alleles tend to present similar sever-
ity. Beyond a correlation in this cohort of adult patients
with a predominant neurological phenotype, it is to note
that some genotypes weren’t represented, suggesting
that certain mutations are always implicated in severe
phenotypes (as V231M as exemple) [31]. Moreover, R141H
is the most frequent allele and known to be associated with
very low residual activity of PMM2 [32,33] and genotypes
including this allele tend to be more severe than these
without.Conclusion
We confirm that CDG screening should be a part of the
routine workup of adolescent/adult patients with spor-
adic or presumably autosomal recessive cerebellar ataxia,
even in the absence of other suggestive signs. We would
also recommend that PMM2-CDG patients have: an
annual biological workup (including blood calcium, T4
TSH, blood cell count, liver and renal analysis), an
annual ophthalmological and neurological clinical as-
sessment, and an evaluation in physical and rehabilita-
tion medicine. Bone densitometry should be proposed at
least once in adulthood and we recommend calcium sup-
plementation. Thrombosis prevention should be discussed
in any predisposing situations.
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